Table 7 Hazard ratios (95% Confidence Intervals) of Outcomes in Matched Cohorts of Dabigatran and Rivaroxaban low and standard doses in Non-Valvular Atrial Fibrillation
| Â | Patients Eligible for low dose but taking standard dose vs. those taking low dose | Patients Eligible for Standard dose but taking low dose vs. those taking dose standard dose | ||||
|---|---|---|---|---|---|---|
Received Low Dose Events (Events/year) | Received Standard Dose Events (Events/year) | 95% Confidence Interval, p-value | Received Low Dose Events (Events/year) | Received Standard Dose Events (Events/year) | 95% Confidence Interval, p-value | |
Ischemic Stroke | ||||||
 Dabigatran | ||||||
Unadjusted | 25 (0.059) | 57 (0.043) | 0.77 (0.47–1.26; p = 0.3) | 59 (0.051) | 319 (0.042) | 1.2 (0.92–1.6, P = 0.17) |
Propensity Matched | 22 (0.059) | 28 (0.061) | 1.13 (0.63–2; p = 0.69) | 55 (0.049) | 88 (0.071) | 0.74 (0.53–1.04; p = 0.08) |
 Rivaroxaban | ||||||
Unadjusted | 176 (0.057) | 161 (0.043) | 0.87 (0.7–1.1; p = 0.2) | 89 (0.040) | 256 (0.026) | 1.36 (1.07–1.7, P = 0.01) |
Propensity Matched | 103 (0.048) | 128 (0.053) | 1.24 (0.96–1.6; p = 0.1) | 78 (0.040) | 73 (0.030) | 1.13 (0.83–1.56, P = 0.43) |
Major Bleeding | ||||||
 Dabigatran | ||||||
Unadjusted | 62 (0.1456) | 124 (0.093) | 0.69 (0.51–0.94; p = 0.02) | 82 (0.071) | 393 (0.051) | 1.35 (1.06–1.7, p = 0.01) |
Propensity Matched | 46 (0.1228) | 58 (0.1258) | 1.07 (0.7–1.58 P = 0.75) | 78 (0.069) | 92 (0.075) | 1.01 (0.74–1.37, P = 0.97) |
 Rivaroxaban | ||||||
Unadjusted | 307 (0.099) | 294 (0.079) | 0.95 (0.8–1.1, P = 0.5) | 147 (0.067) | 426 (0.043) | 1.35 (1.12–1.6, P = 0.001) |
Propensity Matched | 197 (0.091) | 216 (0.089) | 1.12 (0.92–1.35, P = 0.26) | 131 (0.068) | 116 (0.048) | 1.2 (0.93–1.53, P = 0.21) |
GI Hemorrhage | ||||||
 Dabigatran | ||||||
Unadjusted | 46 (0.108) | 100(0.075) | 0.75 (0.5–1.07, P = 0.1) | 67 (0.058) | 292 (0.038) | 1.47 (1.13–1.9, P = 0005) |
Propensity Matched | 33 (0.088) | 45 (0.098) | 1.16 (0.74–1.82, P = 0.53) | 63 (0.056) | 68 (0.055) | 1.08 (0.77–1.53, P = 0.66) |
 Rivaroxaban | ||||||
Unadjusted | 243 (0.078) | 227 (0.061) | 0.93 (0.78–1.1, P = 0.4) | 111 (0.050) | 341 (0.034) | 1.28 (1.04–1.6, P = 0.02) |
Propensity Matched | 158 (0.073) | 166 (0.069) | 1.07 (0.86–1.32, P = 0.5) | 97 (0.050) | 96 (0.040) | 1.08 (0.82–1.43, P = 0.58) |
Intracranial Hemorrhage | ||||||
 Dabigatran | ||||||
Unadjusted | < 11 | < 11 | 0.33 (0.12–0.9; p = 0.03) | < 11 | 52 (0.007) | 0.77 (0.33–1.8; p = 0.54) |
Propensity Matched | < 11 | < 11 | 0.63 (0.2–1.99; p = 0.43) | < 11 | 12(0.009) | 0.58 (0.22–1.54; p = 0.27) |
 Rivaroxaban | ||||||
Unadjusted | 25 (0.008) | 26 (0.007) | 0.99 (0.57–1.7; p = 0.96) | 13 (0.006) | 38 (0.004) | 1.33 (0.7–2.5; p = 0.37) |
Propensity Matched | 17 (0.008) | 22 (0.009) | 1.26 (0.67–2.38; p = 0.47) | 12 (0.006) | < 11 | 1.57 (0.64–3.84; p = 0.32) |